Etoposide quinone is a covalent poison of human topoisomerase IIβ

Biochemistry

Volumn 53, Issue 19, 2014, Pages 3229-3236

  Smith, Nicholas A ^a   Byl, Jo Ann W ^a   Mercer, Susan L ^a   Deweese, Joseph E ^a,b   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LIPSCOMB UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMOLECULES; ENZYMES; METABOLITES; PATIENT MONITORING;

ACUTE MYELOID LEUKEMIA; BROAD SPECTRUM; DRUG METABOLITES; ENZYME-MEDIATED; HUMAN TOPOISOMERASE; MOLECULAR BASIS; SINGLE-STRANDED BREAKS; TOPOISOMERASE II;

DRUG INTERACTIONS;

DNA; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; ETOPOSIDE; HUMANS; LEUKEMIA; NEOPLASM PROTEINS; QUINONES; TOPOISOMERASE II INHIBITORS;

EID: 84901036292     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi500421q     Document Type: Article

References (81)

1. Hande, K. R. (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor Eur. J. Cancer 34, 1514-1521
2. Baldwin, E. L. and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer Curr. Med. Chem.: Anti-Cancer Agents 5, 363-372
3. Deweese, J. E. and Osheroff, N. (2009) The DNA cleavage reaction of topoisomerase II: Wolf in sheeps clothing Nucleic Acids Res. 37, 738-749
4. Nitiss, J. L. (2009) Targeting DNA topoisomerase II in cancer chemotherapy Nat. Rev. Cancer 9, 338-350
5. Pommier, Y., Leo, E., Zhang, H., and Marchand, C. (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chem. Biol. 17, 421-433
6. Pommier, Y. and Marchand, C. (2012) Interfacial inhibitors: Targeting macromolecular complexes Nat. Rev. Drug Discovery 11, 25-36
7. Champoux, J. J. (2001) DNA topoisomerases: Structure, function, and mechanism Annu. Rev. Biochem. 70, 369-413
8. Nitiss, J. L. (2009) DNA topoisomerase II and its growing repertoire of biological functions Nat. Rev. Cancer 9, 327-337
9. Liu, Z., Deibler, R. W., Chan, H. S., and Zechiedrich, L. (2009) The why and how of DNA unlinking Nucleic Acids Res. 37, 661-671
10. Vos, S. M., Tretter, E. M., Schmidt, B. H., and Berger, J. M. (2011) All tangled up: How cells direct, manage and exploit topoisomerase function Nat. Rev. Mol. Cell Biol. 12, 827-841
11. Gentry, A. C. and Osheroff, N. (2013) DNA topoisomerases: Type II. In Encyclopedia of Biological Chemistry, pp 163-168, Elsevier Inc., Amsterdam.
12. Pendleton, M., Lindsey, R. H., Jr., Felix, C. A., Grimwade, D., and Osheroff, N. (2014) Topoisomerase II and leukemia Ann. N.Y. Acad. Sci. 1310, 98-110
13. Felix, C. A., Kolaris, C. P., and Osheroff, N. (2006) Topoisomerase II and the etiology of chromosomal translocations DNA Repair 5, 1093-1108
14. Joannides, M. and Grimwade, D. (2010) Molecular biology of therapy-related leukaemias Clin. Transl. Oncol. 12, 8-14
15. Joannides, M., Mays, A. N., Mistry, A. R., Hasan, S. K., Reiter, A., Wiemels, J. L., Felix, C. A., Coco, F. L., Osheroff, N., Solomon, E., and Grimwade, D. (2011) Molecular pathogenesis of secondary acute promyelocytic leukemia Mediterranean Journal of Hematology and Infectious Diseases 3, e2011045
16. Ezoe, S. (2012) Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor Int. J. Environ. Res. Public Health 9, 2444-2453
17. Cowell, I. G. and Austin, C. A. (2012) Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents Int. J. Environ. Res. Public Health 9, 2075-2091
18. DeVore, R., Whitlock, J., Hainsworth, J. D., and Johnson, D. H. (1989) Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q Ann. Int. Med. 110, 740-742
19. Pui, C. H., Ribeiro, R. C., Hancock, M. L., Rivera, G. K., Evans, W. E., Raimondi, S. C., Head, D. R., Behm, F. G., Mahmoud, M. H., and Sandlund, J. T. 1991, Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia N. Engl. J. Med. 325, 1682-1687
20. Smith, M. A., Rubinstein, L., and Ungerleider, R. S. (1994) Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risks Med. Pediatr. Oncol. 23, 86-98
21. Relling, M. V., Yanishevski, Y., Nemec, J., Evans, W. E., Boyett, J. M., Behm, F. G., and Pui, C. H. (1998) Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia Leukemia 12, 346-352
22. Smith, M. A., Rubinstein, L., Anderson, J. R., Arthur, D., Catalano, P. J., Freidlin, B., Heyn, R., Khayat, A., Krailo, M., Land, V. J., Miser, J., Shuster, J., and Vena, D. (1999) Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins J. Clin. Oncol. 17, 569-577
23. Pedersen-Bjergaard, J. and Philip, P. (1991) Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II Blood 78, 1147-1148
24. Pedersen-Bjergaard, J. and Rowley, J. D. (1994) The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation Blood 83, 2780-2786
25. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs Biochim. Biophys. Acta 1400, 233-255
26. Felix, C. A. (2009) A safer regimen for high-risk neuroblastoma Pediatric Blood & Cancer 53, 3-6
27. Lovett, B. D., Strumberg, D., Blair, I. A., Pang, S., Burden, D. A., Megonigal, M. D., Rappaport, E. F., Rebbeck, T. R., Osheroff, N., Pommier, Y. G., and Felix, C. A. (2001) Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints Biochemistry 40, 1159-1170
28. Wang, M., Wu, W., Rosidi, B., Zhang, L., Wang, H., and Iliakis, G. (2006) PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways Nucleic Acids Res. 34, 6170-6182
29. Wray, J., Williamson, E. A., Singh, S. B., Wu, Y., Cogle, C. R., Weinstock, D. M., Zhang, Y., Lee, S. H., Zhou, D., Shao, L., Hauer-Jensen, M., Pathak, R., Klimek, V., Nickoloff, J. A., and Hromas, R. (2013) PARP1 is required for chromosomal translocations Blood 121, 4359-4365
30. Gomez-Herreros, F., Romero-Granados, R., Zeng, Z., Alvarez-Quilon, A., Quintero, C., Ju, L., Umans, L., Vermeire, L., Huylebroeck, D., Caldecott, K. W., and Cortes-Ledesma, F. (2013) TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo PLoS Genet. 9, e1003226
31. Nitiss, J. L. and Nitiss, K. C. (2013) Tdp2: A means to fixing the ends PLoS Genet. 9, e1003370
32. Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T., Takeda, S., Pommier, Y., and Murai, J. (2014) Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel Mol. Cancer Ther. 13, 214-220
33. Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N. K., Lovett, B. D., Nowell, P. C., Blair, I. A., and Rebbeck, T. R. (1998) Association of CYP3A4 genotype with treatment-related leukemia Proc. Natl. Acad. Sci. U.S.A. 95, 13176-13181
34. Cowell, I. G., Sondka, Z., Smith, K., Lee, K. C., Manville, C. M., Sidorczuk-Lesthuruge, M., Rance, H. A., Padget, K., Jackson, G. H., Adachi, N., and Austin, C. A. (2012) Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity Proc. Natl. Acad. Sci. U.S.A. 109, 8989-8994
35. van Maanen, J. M. S., Retl, J., de Vries, J., and Pinedo, H. M. (1988) Mechanism of action of antitumor drug etoposide: A review J. Natl. Cancer Inst. 80, 1526-1533
36. Relling, M. V., Evans, R., Dass, C., Desiderio, D. M., and Nemec, J. (1992) Human cytochrome P450 metabolism of teniposide and etoposide J. Pharmacol. Exp. Ther. 261, 491-496
37. Relling, M. V., Nemec, J., Schuetz, E. G., Schuetz, J. D., Gonzalez, F. J., and Korzekwa, K. R. (1994) O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4 Mol. Pharmacol. 45, 352-358
38. Zhuo, X., Zheng, N., Felix, C. A., and Blair, I. A. (2004) Kinetics and regulation of cytochrome P450-mediated etoposide metabolism Drug Metab. Dispos. 32, 993-1000
39. Haim, N., Roman, J., Nemec, J., and Sinha, B. K. (1986) Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26) Biochem. Biophys. Res. Commun. 135, 215-220
40. Gantchev, T. G. and Hunting, D. J. (1997) Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16) Biochem. Biophys. Res. Commun. 237, 24-27
41. Gantchev, T. G. and Hunting, D. J. (1998) The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex Mol. Pharmacol. 53, 422-428
42. Kagan, V. E., Yalowich, J. C., Borisenko, G. G., Tyurina, Y. Y., Tyurin, V. A., Thampatty, P., and Fabisiak, J. P. (1999) Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: Free radical/antioxidant approach Mol. Pharmacol. 56, 494-506
43. Fan, Y., Schreiber, E. M., Giorgianni, A., Yalowich, J. C., and Day, B. W. (2006) Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells Chem. Res. Toxicol. 19, 937-943
44. Austin, C. A. and Marsh, K. L. (1998) Eukaryotic DNA topoisomerase IIβ BioEssays 20, 215-226
45. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kDa and 180 kDa forms of topoisomerase II in NIH-3T3 cells Cell Growth Differ. 2, 209-214
46. Christensen, M. O., Larsen, M. K., Barthelmes, H. U., Hock, R., Andersen, C. L., Kjeldsen, E., Knudsen, B. R., Westergaard, O., Boege, F., and Mielke, C. (2002) Dynamics of human DNA topoisomerases IIα and IIβ in living cells J. Cell Biol. 157, 31-44
47. Yang, X., Li, W., Prescott, E. D., Burden, S. J., and Wang, J. C. (2000) DNA topoisomerase IIβ and neural development Science 287, 131-134
48. Ju, B. G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (2006) A topoisomerase IIβ-mediated dsDNA break required for regulated transcription Science 312, 1798-1802
49. Heng, X. and Le, W. D. (2010) The function of DNA topoisomerase IIβ in neuronal development Neurosci. Bull. 26, 411-416
50. McClendon, A. K. and Osheroff, N. (2007) DNA topoisomerase II, genotoxicity, and cancer Mutat. Res. 623, 83-97
51. Pommier, Y. (2013) Drugging topoisomerases: Lessons and challenges ACS Chem. Biol. 8, 82-95
52. Azarova, A. M., Lyu, Y. L., Lin, C. P., Tsai, Y. C., Lau, J. Y., Wang, J. C., and Liu, L. F. (2007) Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies Proc. Natl. Acad. Sci. U.S.A. 104, 11014-11019
53. Worland, S. T. and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae J. Biol. Chem. 264, 4412-4416
54. Elsea, S. H., Hsiung, Y., Nitiss, J. L., and Osheroff, N. (1995) A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine J. Biol. Chem. 270, 1913-1920
55. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints Biochemistry 36, 5934-5939
56. Nemec, J. (1986) Epipodophyllotoxinquinone glucoside derivatives, method of production and use. U.S. Patent 4609644 A.
57. Jacob, D. A., Mercer, S. L., Osheroff, N., and Deweese, J. E. (2011) Etoposide quinone is a redox-dependent topoisomerase II poison Biochemistry 50, 5660-5667
58. Fortune, J. M. and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage J. Biol. Chem. 273, 17643-17650
59. Wilstermann, A. M., Bender, R. P., Godfrey, M., Choi, S., Anklin, C., Berkowitz, D. B., Osheroff, N., and Graves, D. E. (2007) Topoisomerase II-drug interaction domains: Identification of substituents on etoposide that interact with the enzyme Biochemistry 46, 8217-8225
60. Wu, C. C., Li, T. K., Farh, L., Lin, L. Y., Lin, T. S., Yu, Y. J., Yen, T. J., Chiang, C. W., and Chan, N. L. (2011) Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide Science 333, 459-462
61. Pommier, Y., Capranico, G., Orr, A., and Kohn, K. W. (1991) Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide Nucleic Acids Res. 19, 5973-5980
62. Pommier, Y. and Marchand, C. (2005) Interfacial inhibitors of protein-nucleic acid interactions Curr. Med. Chem.: Anti-Cancer Agents 5, 421-429
63. Sinha, B. K., Politi, P. M., Eliot, H. M., Kerrigan, D., and Pommier, Y. (1990) Structure-activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposide Eur. J. Cancer 26, 590-593
64. Jacob, D. A., Gibson, E. G., Mercer, S. L., and Deweese, J. E. (2013) Etoposide catechol is an oxidizable topoisomerase II poison Chem. Res. Toxicol. 26, 1156-1158
65. Wang, H., Mao, Y., Chen, A. Y., Zhou, N., LaVoie, E. J., and Liu, L. F. (2001) Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation Biochemistry 40, 3316-3323
66. Lindsey, R. H., Jr., Bromberg, K. D., Felix, C. A., and Osheroff, N. (2004) 1,4-Benzoquinone is a topoisomerase II poison Biochemistry 43, 7563-7574
67. Bender, R. P., Ham, A. J., and Osheroff, N. (2007) Quinone-induced enhancement of DNA cleavage by human topoisomerase IIα: Adduction of cysteine residues 392 and 405 Biochemistry 46, 2856-2864
68. Bender, R. P. and Osheroff, N. (2007) Mutation of cysteine residue 455 to alanine in human topoisomerase IIα confers hypersensitivity to quinones: Enhancing DNA scission by closing the N-terminal protein gate Chem. Res. Toxicol. 20, 975-981
69. Lin, R. K., Zhou, N., Lyu, Y. L., Tsai, Y. C., Lu, C. H., Kerrigan, J., Chen, Y. T., Guan, Z., Hsieh, T. S., and Liu, L. F. (2011) Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα J. Biol. Chem. 286, 33591-33600
70. Ketron, A. and Osheroff, N. (2014) Phytochemicals as anticancer and chemopreventive topoisomerase II poisons Phytochem. Rev. 13, 19-35
71. Bender, R. P., Lehmler, H. J., Robertson, L. W., Ludewig, G., and Osheroff, N. (2006) Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIα: Altering enzyme function by blocking the N-terminal protein gate Biochemistry 45, 10140-10152
72. Mondrala, S. and Eastmond, D. A. (2010) Topoisomerase II inhibition by the bioactivated benzene metabolite hydroquinone involves multiple mechanisms Chem.-Biol. Interact. 184, 259-268
73. Bender, R. P., Lindsey, R. H., Jr., Burden, D. A., and Osheroff, N. (2004) N-Acetyl- p -benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison Biochemistry 43, 3731-3739
74. Osheroff, N. and Zechiedrich, E. L. (1987) Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: Trapping the covalent enzyme-DNA complex in an active form Biochemistry 26, 4303-4309
75. Long, B. H. (1987) Structure-activity relationships of podophyllin congeners that inhibit topoisomerase II Natl. Cancer Inst. Monogr. 123-127
76. Bender, R. P., Jablonksy, M. J., Shadid, M., Romaine, I., Dunlap, N., Anklin, C., Graves, D. E., and Osheroff, N. (2008) Substituents on etoposide that interact with human topoisomerase IIα in the binary enzyme-drug complex: Contributions to etoposide binding and activity Biochemistry 47, 4501-4509
77. Wang, H., Mao, Y., Zhou, N., Hu, T., Hsieh, T. S., and Liu, L. F. (2001) ATP-bound topoisomerase II as a target for antitumor drugs J. Biol. Chem. 276, 15990-15995
78. Bromberg, K. D., Burgin, A. B., and Osheroff, N. (2003) A two-drug model for etoposide action against human topoisomerase IIα J. Biol. Chem. 278, 7406-7412
79. Long, B. H., Musial, S. T., and Brattain, M. G. (1985) Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide Cancer Res. 45, 3106-3112
80. Muslimovic, A., Nystrom, S., Gao, Y., and Hammarsten, O. (2009) Numerical analysis of etoposide induced DNA breaks PLoS One 4, e5859
81. Sabourin, M. and Osheroff, N. (2000) Sensitivity of human type II topoisomerases to DNA damage: Stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions Nucleic Acids Res. 28, 1947-1954